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Uncultured mesenchymal stromal cells (MSCs) are increasingly used in therapies; however, the eﬀects of donor age on their
biological characteristics and gene expression remain unclear. The aim of this study was to investigate age-related changes in
bone marrow (BM) MSCs following minimal or no culture manipulation. Iliac crest BM was aspirated from 67 healthy donors
(19-89 years old) and directly used for the colony-forming unit-ﬁbroblast (CFU-F) assay or CD45lowCD271+ cell enumeration.
The colonies were analysed for colony area and integrated density (ID) when grown in standard MSC media or media
supplemented with human serum from young (YS) or old (OS) donors. There was a notable age-related decline in the number
of MSCs per millilitre of BM aspirate revealed by the CFU-F assay (r = −0 527, p < 0 0001) or ﬂow cytometry (r = −0 307, p =
0 0116). Compared to young donors (19-40 years old), colony IDs were signiﬁcantly lower in older donors (61-89 years old),
particularly for smaller-sized colonies (42% lower, p < 0 01). When cultured in media supplemented with OS, young and old
donor MSCs formed colonies with lower IDs, by 21%, p < 0 0001, and 27%, p < 0 05, respectively, indicating the formation of
smaller sparser colonies. No signiﬁcant diﬀerences in the expression of selected adipogenic, osteogenic, stromal, and bone
remodelling genes as well as CD295, CD146, CD106, and connexin 43 surface molecules were found in sorted CD45lowCD271+
MSCs from young and old donors (n = 8 donors each). Altogether, these results show similar trends for age-related decline in
BM MSC numbers measured by the CFU-F assay and ﬂow cytometry and reveal age-related eﬀects of human serum on MSC
colony formation. No signiﬁcant diﬀerences in selected gene expression in uncultured CD45lowCD271+ MSCs suggest that old
donor MSCs may not be inferior in regard to their multipotential functions. Due to large donor-to-donor variation in all donor
groups, our data indicate that an individual’s chronological age is not a reliable predictor of their MSC number or potency.
1. Introduction
Mesenchymal stromal cells (MSCs) are being extensively
used as cell therapy or in combination with scaﬀolds, for
the treatment of multiple disorders, owing to their multiline-
age diﬀerentiation and trophic and immunomodulation abil-
ities [1]. Current challenges in this ﬁeld include a better
understanding of MSC tissue diversity, their tissue-speciﬁc
phenotypes, the impact of aging, and the development of
novel protocols for the enhancement of their reparative func-
tions. More recently, strategies based on MSC secretome
including extracellular vesicles (EVs) have been proposed
as a cell-free alternative [2]. Most of the current treatments
utilize large numbers of MSCs and therefore require their
large-scale culture expansion. More recent therapies, partic-
ularly those for bone and cartilage regeneration, have begun
to employ minimally manipulated, autologous MSCs in the
form of bone marrow (BM) aspirates or concentrates or
loading them on scaﬀolds [3, 4]. During prolonged cultiva-
tion in standard conditions, MSCs undergo an in vitro aging
Hindawi
Stem Cells International
Volume 2019, Article ID 5197983, 14 pages
https://doi.org/10.1155/2019/5197983
process, the highlights of which include telomere erosion
[5], gene methylation [6], accumulation of senescent cells
[7, 8], and harmful modulation of themembrane glyceropho-
spholipid composition [9]. In combination, this ultimately
leads to a gradual loss of potency including MSC homing
[10], migration [11, 12], and diﬀerentiation capabilities [13]
commonly described as MSC “in vitro aging.” In contrast,
our understanding of how MSC “age” in vivo, especially in
humans, is limited [13, 14] but remains a key challenge par-
ticularly for the translation of minimally manipulated MSC
therapies [2].
Most commonly, in vivo aging of human MSCs has been
investigated indirectly, by comparing the rates of their
in vitro aging and showing that it happens faster in cultures
derived from older individuals compared to cultures from
younger donors [15–17]. This indirectly indicates that older
donor MSCs might have already “aged” in vivo and thus
require fewer rounds of in vitro cell division prior to reaching
senescence. The idea that BM MSCs might “age” in vivo is
also supported by the fact that several diseases of the muscu-
loskeletal system such as osteoporosis and osteoarthritis are
signiﬁcantly more prevalent in older individuals [18, 19].
To test whether BM MSC numbers decline with age, many
studies performed the classical colony-forming unit-
ﬁbroblast (CFU-F) assay, which has produced, over the years,
somewhat conﬂicting results: decline [20–22] or no decline
[23–25], which can be explained by diﬀerent protocols used
for BM aspiration and processing, as well as variable assay
conditions and the diﬀerences in colony scoring methods.
Even with the assumption that BM MSCs decline with age,
it remains unclear whether this possible reduction is due to
the preferential loss of the most proliferative cells or is a
result of the nonspeciﬁc decline in all types of colony-
forming progenitors. The data on quantiﬁcation of BMMSCs
using ﬂow cytometry based on the speciﬁc MSC surface phe-
notype also remains limited [26–30] and requires further
independent veriﬁcation between diﬀerent laboratories.
Similarly, the relationships between donor age and their
MSC gene expression, prior to cultivation, remain poorly
understood. The literature pertaining to cultured MSCs sug-
gests a potential shift from their osteogenic to adipogenic fate
with increasing donor age [13, 31]; however, this has not
been conﬁrmed using uncultured MSCs. Finally, several
studies utilizing cultured MSCs have proposed certain sur-
face molecules associated with MSC “youthful” or “aged” sta-
tus, including CD106 [32], CD146 [17], or CD295 [33], but
these molecules have not been comprehensively studied on
uncultured MSCs in relation to donor age. In this study, we
hypothesised that age-related changes in BM MSCs are asso-
ciated with a preferential loss of the most proliferative clono-
genic progenitors and that their gene expression proﬁle
reﬂects a shift from osteogenesis and hematopoietic stromal
support activity to adipogenesis. We also hypothesised that
MSCs from older individuals possessed higher levels of
CD295 expression mirroring previous ﬁndings obtained
from culturedMSCs [33], as well as the reduced levels of con-
nexin 43, based on our previous gene expression data [34].
To investigate this, we used the classical CFU-F assay as
well as ﬂow cytometry/cell sorting for the CD45lowCD271+
cell population, a recognized phenotype of human BMMSCs
[26, 28, 29, 35, 36]. Previous independent studies have docu-
mented that this cell subset fully fulﬁls the MSC criteria as
stipulated by the International Society for Cell Therapy posi-
tion statement [37]: the expression of CD73/CD90/CD105
[34, 38, 39], high-level enrichment on colony-forming cells
[39, 40], and multipotential diﬀerentiation capacity [34, 40].
We used a large cohort of BM donors aged from 19 to 89
years old, who underwent surgeries for orthopaedic trauma
or metalwork removal, but were otherwise healthy. The
CFU-F assay was performed volumetrically, without addi-
tional processing steps that could have led to the loss of MSCs
[27], and the colonies were further analysed for colony areas
and integrated densities, in order to discern any diﬀerences in
CFU-F distribution, in relation to donor age. The eﬀects of an
“aging environment” on MSC colony formation were further
analysed using media supplemented with human serum.
2. Methods
2.1. Sample Collection and CFU-F Assay. Ethical approval for
the collection of samples was obtained fromNREC Yorkshire
and Humberside National Research Ethics Committee
(number 06/Q1206/127). Bone marrow aspirate (BMA,
10ml) was collected from the iliac crest (IC) of 33 female
and 34 male patients with a median age of 49 years (range
19-89) and used immediately upon receipt. The donors were
admitted at the Leeds General Inﬁrmary for orthopaedic
surgery, and donors with any metabolic diseases, systemic
illness, or cancer were excluded. All the aspirations were per-
formed by the same surgeon and under the same conditions
for consistency.
BMA was ﬁrst passed through a sterile 70 μm cell
strainer (Falcon, Fisher Scientiﬁc, Loughborough, UK) to
exclude fat or bone debris. Subsequently, enumeration of
MSCs was performed using the CFU-F assay and ﬂow
cytometry followed by freezing of the remaining nucleated
cells after ammonium chloride lysis of erythroid lineage
cells, as described previously [41]. In brief, ammonium
chloride was added to BMA in an 8 : 1 ratio and incubated
at 37°C for 10 minutes. The cells were then washed three
times with phosphate-buﬀered saline (PBS, Life Technolo-
gies, Paisley, UK) then frozen.
For the CFU-F assay, 80 μl of BMA was added directly
into each of the duplicate 60mm petri dishes (Corning,
New York, USA) containing 4ml of StemMACS MSC
expansion media (SM) (Miltenyi Biotec, Bisley, UK) with
1% Penicillin-Streptomycin (P/S, Thermo Scientiﬁc, Lough-
borough, UK). Following the mixing of BMA and media,
dishes were placed in the incubator in 37°C and 5% CO2
and maintained in culture for two weeks. After 48 hours,
the dishes were gently washed with PBS and 4ml of fresh
SM was added. Thereafter, half media change was per-
formed twice a week, and on the 14th day, the resulting col-
onies were ﬁxed with 3.7% formaldehyde (Fisher Scientiﬁc,
Loughborough, UK) stained with 1% w/v methylene blue
(Sigma, Dorset, UK) and scanned. A colony was deﬁned
as consisting of at least 50 cells [29]. The colonies were
manually counted and CFU-F/ml was calculated according
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to the formula 1000 μl × average number of colonies from 2
dishes / 80μl, and the results were plotted against donor’s
age for correlation. Additionally, the analysis was per-
formed between three diﬀerent age groups denoted as
young (19-40 years old), intermediate age (41-60 years
old), and old (61-89 years old), as deﬁned in previous stud-
ies [16, 20, 21].
2.2. Analysis of Colony Area and Integrated Density. Colony
sizes and densities have been previously reported to reﬂect
individual MSC’s proliferative capacities [42, 43]. To investi-
gate this in relation to donor age, CFU-F dishes with similar
numbers of colonies (average 40 colonies per dish, range 25-
60) from the young and old age groups (n = 7 donors each)
were analysed for colony area and integrated density (ID).
The images of scanned dishes were converted to “grey scale”
to be recognized by ImageJ software, which generated an out-
line for each colony. In order to avoid the inﬂuence of the
background disturbances and to minimize software error
(for example, by counting two overlapping colonies as one),
the colonies on the edges of the dish were given an outline
manually. The values for colony area and ID were generated
simultaneously, and IDs were calculated as [area∗mean grey
value]. Once the data for colony area and ID were recorded,
the data were compared between the young and old donor
groups. For the subsequent analysis, colonies were segregated
as small or large based on the median value obtained from all
colonies (below and above the median, respectively), and
their IDs were analysed separately and also in relation to
donor age.
2.3. MSC Colony Formation in Media Containing Human
Serum. To investigate the proliferative capacity of MSCs that
would mirror conditions in vivo, human serum was prepared
and used as the in vivo microenvironment. The aim of these
experiments was to investigate how young and old donor
MSCs responded to young and old donor human serum in
terms of their colony numbers, areas, and IDs. To prepare
human serum, 30ml of blood was collected from 4 healthy
old (59-62 years old) and 4 healthy young (23-31 years old)
donors and serum was prepared by spinning the blood at
2000g for 15 minutes. Subsequently, 4 sera were pooled
together to generate stocks of old donor serum (OS) and
young donor serum (YS) separately, which were then ali-
quoted and frozen at -20°. Media containing either 10% YS
or 10% OS were prepared fresh using DMEM as the basal
media (Life Technologies, Paisley, UK) and supplemented
with 1% P/S.
Frozen nucleated cells (from donors with at least 107
frozen cells) were defrosted at 37°C in thawing media
(DMEM/10% FCS) (Thermo Scientiﬁc, Loughborough, UK)
containing 1% P/S and 20 units/ml DNAse (Sigma, Dorset,
UK). Following centrifugation, the cells were equally divided
into nine 60mm dishes containing 4ml SM for an initial
48-hour attachment period. Subsequently, the media were
removed, the adherent cells washed with PBS, and complete
media changes were performed as follows: 3 dishes were sup-
plemented with 4ml DMEM/10% YS, 3 dishes with 4ml of
DMEM/10% OS, and 3 ﬁnal dishes with 4ml SM (control).
The dishes were then placed at 37°C and 5% CO2 for 2 weeks,
and half media changes were performed using the respective
media twice a week. On day 14, all media were aspirated,
and for each condition, two dishes were stained with meth-
ylene blue to visualise the colonies, while the adherent cells
from the third dish were detached using trypsin (Life Tech-
nologies, Paisley, UK) and counted. The stained dishes were
analysed for colony area and ID, as described in the previ-
ous section.
2.4. Enumeration of BM MSCs Using CD45lowCD271+
Phenotype. MSC enumeration by ﬂow cytometry was per-
formed on the same cohort of donors in order to directly
compare the data with the results of the CFU-F assay. For
this, 100 μl of BMA was placed in a FACS tube (Falcon) con-
taining 20μl CD271-allophycocyanine (APC) (Miltenyi Bio-
tec) and 20 μl CD45-phycoerythrin- (PE-) cyanine dye 7
(Cy7) (BD Pharmingen, Oxford, UK) for 15 minutes at room
temperature (RT); 10μl of 7-Aminoactinomycin-D (7-AAD,
BD Pharmingen) was added simultaneously in order to dis-
tinguish between live and dead cells. After staining, erythroid
lineage cells were lysed using ammonium chloride (Sigma,
Dorset, UK) at 37°C for 10 minutes. Finally, 50 μl of CountB-
right absolute counting beads (Life Technologies) was added
at RT after a quick vortex for 5-7 seconds, as previously
described [27]. The data were acquired using the Becton
Dickinson (BD) LSRII 4 laser ﬂow cytometer. Unstained
and single antibody-stained controls were used to optimize
the cytometer voltage settings and spectral compensation,
and isotype controls (IgG1-APC and IgG1-PE-Cy7, BD
Pharmingen) were used to gate for MSCs. The analysis
of the ﬂow cytometry data was performed using the FACS
Diva software (BD Biosciences, Oxford, UK), as previously
described [27].
2.5. Cell Sorting and Surface Marker Expression Analysis.
Frozen nucleated cells were defrosted (n = 8 donors from
each young and old groups), and MSCs were enriched using
Anti-Fibroblast beads (Miltenyi Biotec), as previously
described [34]. Enriched cells were treated with Fc block
(Miltenyi Biotec) for 10 minutes to prevent nonspeciﬁc anti-
body binding and then stained with the following antibodies
for 15 minutes: 20 μl CD45 V450, 20μl CD271 PE Vio770,
20 μl CD106 PE, and 10μl CD295 Alexa Fluor 647 (panel
1); or 20μl CD45 V450, 20μl CD271 PE Vio770, 20μl
CD146 PE (all from BD Pharmingen, Oxford, UK), and
10μl Cx43 APC (R&D Systems, Minneapolis, USA) (panel
2). Isotype controls for each antibody were used to control
for nonspeciﬁc antibody binding. After staining, the cells
were washed in FACS buﬀer and passed through the
ﬁltered-cap ﬂow tubes (Falcon) to remove any cellular
clumps. Finally, 10 μl of 7-AAD was added to all the tubes
prior to cell sorting using BD Inﬂux cell sorter.
Instrument settings and spectral compensations were
performed using unstained cells, compensation beads, and
isotype controls. Cells were sorted into 2 tubes to collect
the following populations: CD45lowCD271+ (MSCs) and
CD45highCD271- (hematopoietic lineage cells or HLCs), as
previously described [34]. Sorted cells were directly collected
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into 1.5ml Eppendorf tubes containing 350 μl guanidinium-
based lysis buﬀer (Buﬀer RL, Norgen, Thorold, Canada),
and lysates were frozen at -80° for subsequent RNA extrac-
tion and qPCR. Surface marker expression on gated
CD45lowCD271+ MSCs and CD45highCD271- (HLCs) was
analysed using FlowJo Software (BD, version 10).
2.6. Gene Expression. RNA was extracted from cell lysates
(obtained from cell sorts) using Single Cell RNA Puriﬁca-
tion Kit (Norgen Biotek, Canada) following manufacturer
instructions with genomic DNA removal using DNAse I
from the same company. RNA was eluted in 15 μl of elution
solution, evaluated for its concentration and integrity using
Nanodrop and stored in -80°C until further use. 2μl of RNA
was reversely transcribed (RT) to cDNA using RT reagent
(Fluidigm, California, USA), and the reaction was carried
out in thermal cycler (Applied Biosystems, California, USA)
under the following conditions: 5min at 25°C, 30min at
42°C, 5min at 85°C, and then held at 4°C. cDNA was stored
in -20°C until analysis. For preampliﬁcation (PA), a mixture
of 12 TaqMan Gene Expression assays (Applied Biosystems)
at a ﬁnal concentration of 0.2x for each assay (Supplementary
Table 1) was prepared with the PA reagent (Fluidigm) and
1.25 μl of cDNA. All samples were preampliﬁed in the
thermocycler using 18 cycles polymerised chain reaction
(PCR) following the settings 2min at 95°C, 15 sec at
95°C, 4min at 60°C, and then held at 4°C. After
preampliﬁcation PCR cDNA was diluted 1 : 5 with Tris
and Ethylenediaminetetraacetic acid (TE) buﬀer and was
stored at −20°C before processing on the BioMark HD.
Quantitative PCR (qPCR) was performed using Fluidigm
FLEXSIX™ integrated ﬂuid circuits (IFC) on BioMark HD.
For qPCR, 2 μl of each TaqMan assay was mixed with 2μl
Gene Expression Assay Loading Reagent (Fluidigm). Then,
1.8 μl of diluted cDNA was mixed with 2μl 2× TaqMan
Universal Mastermix (Thermo Fisher) and 0.2μl Gene
Expression Sample Loading Reagent (Fluidigm). Next, 3μl
of each sample and assay was loaded into individual sample
and assay inlets on the IFC. Samples and assays were then
loaded into the reaction chambers of the FLEXSIX using
the IFC Controller HX (Fluidigm) and then transferred to
the BioMark HD for qPCR (95°C for 10min; 40 cycles of
95°C for 15 seconds, and 60°C for 60 sec). The Ct values for
genes of interest were normalised to the endogenous
control HPRT-1 using the formula ΔCt = Cttarget gene −
Cthousekeeping gene , and relative expression was calculated as
2-ΔCt and used for statistical analysis.
2.7. Statistics. Statistical analysis and graphics were per-
formed using GraphPad Prism software (version 7.0a). The
normal distribution of the data was assessed using the
Shapiro-Wilk and Kolmogorov-Smirnov tests for normality.
As no data were found to be normally distributed, Mann-
Whitney test and Kruskal-Wallis test with Dunn’s correction
for multiple comparisons were used to compare two and
three groups, respectively. Spearman test was used to ana-
lyse correlations. The results were considered signiﬁcant at
p value of <0.05.
3. Results
3.1. MSC Enumeration and Colony Characterisation Using
Standard CFU-F Assay. BM MSCs from 62 donors (n = 33
females, n = 29 males) were ﬁrst quantiﬁed using the stan-
dard CFU-F assay following a 14-day culture in SM media,
and a signiﬁcant age-related decline in the number of colo-
nies was found (r = −0 527, p < 0 0001) (Figure 1(a), left
panel). When the whole cohort was divided into three age
groups, young (19-40), intermediate age (41-60), and old
(61-89 years old), a signiﬁcant 4.2-fold decline was observed
in the number of MSCs in the old group (median 37CFU-
F/ml) compared to the young group (median 156CFU-
F/ml) as well as a 3.5-fold decline in the intermediate age
group (median 45CFU-F/ml) compared to the young group
(Figure 1(a), right panel). There was no statistically signiﬁ-
cant diﬀerence in the average number of colonies between
donors of the intermediate age group and the old group for
all donors, as well as when separating male and female
cohorts (Figure 1(a)). Notably, high donor-to-donor varia-
tion was observed in all donor groups, and some old donors
had CFU-F numbers within the range of the young donor
group (Figure 1(a), right panel).
To investigate whether a decline in colony number in the
old donor group was associated with a speciﬁc loss of the
most proliferative progenitors, colony area and ID analysis
was performed on the CFU-F dishes from 7 young and 7
old donors containing a minimum of 25 colonies per dish.
A total of 587 colonies (266 and 321 colonies from the old
and young groups, respectively) were analysed using ImageJ
and revealed CFU-F colonies of vastly diﬀerent sizes in both
age groups (Figure 1(b), left panel). However, colonies from
the old group were on average 10% smaller than colonies
from young donors (Figure 1(b), right panel). The frequency
distribution of colony areas was next performed using
GraphPad Prism software by generating a nonlinear ﬁt line
based on modal values of predeﬁned bin widths of 5mm2.
This analysis revealed unimodal colony area distributions
in both young and old cohorts; however, a prominent shift
towards smaller colonies was observed in the old group
(Figure 1(c), left panel).
Colonies with the smallest sizes and lowest densities have
previously been suggested to derive from the least prolifera-
tive, presenescent progenitor cells [43]. As colony’s ID is a
combined measure of colony’s size and its density, the largest
ID values indicate large, dense colonies (i.e., derived from the
most proliferative MSCs), while the smallest ID values corre-
spond to small, sparse colonies (derived from the least prolif-
erative MSCs) [42]. To further investigate these colony types
in relation to donor age, the median area of all 587 colonies
(10.64mm2) was set as the cutoﬀ point to separate smaller
and larger colonies, and their IDs were compared between
the donor groups (Figure 1(c), right panel). For both, smaller
and larger colonies, their IDs were signiﬁcantly lower in the
old donors (42% and 18% lower, respectively); however, the
largest decline in IDs was observed for smaller colonies
(Figure 1(c), right panel).
Altogether, CFU-F data revealed a gradual age-related
decline in the number of colony-forming MSCs, as well as
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Figure 1: Age-related decline in number and proliferative capacity of BM MSCs. (a) Correlation between CFU-Fs/ml of BM aspirate
with donor age across complete age range (left, n = 62 donors, 19-89 years old) and between three age groups (right); black lines
indicate the line of the best ﬁt (left) and median values for each group (right). (b) Representative colony dish showing the presence
of large and small colonies (left) and comparison of colony areas in all colonies in 7 young donors (19-37 years old, 321 colonies)
and 7 old donors (61-76 years old, 266 colonies) (right). Each dot represents a single colony; black lines represent median values.
(c) Frequency distribution of colony areas for colonies from the same 7 young (black curve) and 7 old donors (grey curve) (left)
and comparison of integrated densities (IDs) of smaller colonies (left) and larger colonies (right) in the young and old donor groups.
∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001, and ∗∗∗∗p < 0 0001.
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colony areas and IDs (particularly for smaller colonies), indi-
cating increased proportions of less proliferative MSCs in old
donors BM.
3.2. MSC Enumeration and Colony Characterisation in
Conditions Containing Human Serum. Although the CFU-F
assay conducted in media preselected for enhanced MSC
growth still represents the “gold standard” for MSC enumer-
ation [44], cell cultivation is notably performed in conditions
drastically diﬀerent to which they are normally exposed
in vivo. To mimic old donor MSC exposure to their more
natural environment, CFU-F assays were next conducted in
media containing human serum. The assays were performed
using frozen/thawed nucleated cells from the young and old
donor groups, which were all initially plated in SM to allow
for equal attachment and 48 hours later transferred to media
containing pooled human serum from either young (YS) or
old (OS) donors, or SM as controls. A total of 1517 colonies
were analysed in these experiments, 932 and 586 from the
young and old donor groups, respectively. In addition to
staining dishes and analysing colony data, the cells from the
third dish were trypsinised and counted to obtain data on
the produced total cell yields (Figure 2).
The numbers of colonies grown in media supplemented
with human serum were similar to SM conditions and
showed no signiﬁcant diﬀerence between YS and OS condi-
tions, in both young and old donors (Figure 2(a)). However,
the analysis of cell counts obtained from the third dish
revealed a trend for a decline in the number of cells obtained
from both young and old donor groups when cultured in
OS as compared to YS (Figure 2(b)) indicating the reduced
proliferation of MSCs in OS. Cell counts obtained from
dishes grown in YS conditions were similar to control SM
conditions (Figure 2(b)). To dissect this further, colony area
and ID analysis was performed on all colonies. In the
young donor group, the frequency distributions of colony
areas were quite similar for OS or YS culture conditions
(Figure 2(c), left panel), with the most frequent colonies
being larger in area than colonies grown in SM (dashed line).
However, in the old donor group, OS conditions have led to
shift towards smaller colonies, which became even smaller
than SM colonies (Figure 2(c), right panel). Of note, colony
distributions in SM from frozen cells (Figure 2(c)) were dif-
ferent to colony distributions from fresh cells (Figure 1(c))
possibly due to the fact that frozen/thawed cells required
some time to recover from the frozen state before they began
proliferating and forming a colony.
In the young donors’ group, the ID of colonies grown in
YS was signiﬁcantly 21% higher (p < 0 0001) compared to OS
conditions and signiﬁcantly 31% higher (p < 0 0001) com-
pared to SM conditions (Figure 2(d)). In the old donors’
group, the ID of colonies grown in YS was similarly, signiﬁ-
cantly 27% higher (p < 0 05) compared to OS conditions,
but diﬀerences in colony IDs in comparison to SM were
not statistically signiﬁcant (Figure 2(e)).
3.3. MSC Enumeration and Gene Expression Using
CD45lowCD271+ Phenotype. We and the others have previ-
ously reported that all CFU-Fs in human BM are present in
a rare cell population characterised by the CD45lowCD271+
phenotype [26, 40]. BM MSCs from the same cohort of
donors were next enumerated using CD45lowCD271+ phe-
notype (Figure 3(a)). Similar to our CFU-F data, there was
an age-related decline in the numbers of CD45lowCD271+
cells (r = −0 307, p = 0 0116); however, the slope of the
decline was much shallower (Figure 3(a), left panel). When
the whole cohort was divided into three age groups, young,
intermediate age, and old, there was a 2.2-fold decline in
the number of CD45lowCD271+ cells in old donors (median
1825 cells/ml) and a 2.6-fold decline in donors from inter-
mediate age (median 1587 cells/ml) compared to young
donors (median 4103 cells/ml) (Figure 3(a), middle panel),
a pattern similar to CFU-Fs, but failing to reach statistical
signiﬁcance. As expected [27, 29], there was a strong positive
correlation between CFU-F and CD45lowCD271+ cell counts
(r = 0 606, p < 0 0001) (Figure 3(a), right panel). Based on
the respective median values, the CFU-F/CD45lowCD271+
cell ratios were 1 in 26 in young donors, 1 in 35 in donors
of intermediate age, and 1 in 48 in old donors suggesting
an age-related decline in the colony-forming ability of
CD45lowCD271+ cells.
In terms of their gene expression, there was no signiﬁcant
diﬀerence in the expression of selected transcripts related to
osteogenic or adipogenic diﬀerentiation (Figure 3(b)). We
also found no diﬀerences in transcripts associated with cellu-
lar interaction (Figure 3(c)) or bone remodelling (Figure 3(d))
in CD45lowCD271+ cells. However, the trend for increased
RANKL and OPG was noted in CD45lowCD271+ cells from
old donors, as well as signiﬁcantly higher RANKL in old
donor HLCs (Figure 3(d)). Transcripts of OPG and SFRP-1
could not be detected in HLCs while the remaining molecules
were signiﬁcantly higher in CD45lowCD271+ cells compared
to HLCs (Supplementary Table 2) conﬁrming their MSC
speciﬁc identity.
3.4. Leptin Receptor, Cx43/Connexin 43, and Other Surface
Marker Expression in CD45lowCD271+ Cells. The leptin
receptor/CD295 and Cx43/connexin 43 expression on uncul-
tured human BMMSCs was next analysed using ﬂow cytom-
etry. Also, the expression of two other markers CD146 and
CD106 previously linked to MSC “youthful” or “aged”
[21, 34] status was assessed simultaneously. Population
gating was performed on CD45lowCD271+ cells (MSCs) and
control CD45highCD271- cells (HLCs) (Figures 4(a) and
4(b), left panels). The expression of CD295, CD146, and
CD106 was signiﬁcantly higher in MSCs compared to HLCs
(Supplementary Table 2). Representative histograms are
shown in Figures 4(a) and 4(b). However, there were no
age-related diﬀerences in the level of expression of any of
these molecules in MSCs as well as HLCs (Figure 4(c)).
4. Discussion
There is a signiﬁcant body of literature investigating the
phenomenon on in vitro aging of human BM MSCs. In
accumulation, it describes the gradual loss of proliferation,
telomere erosion, and the modulation of MSC gene and pro-
tein expression, as a consequence of accrued population
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doublings (commonly 20-40) [14, 44, 45]. On the other
hand, the evidence of human BM MSC “aging” in vivo
remains scarce. It is commonly extrapolated indirectly from
histological, serological, and functional studies of unfractio-
nated bone or BM samples from young and aged donors and
suggests “diﬀerentiation reprogramming of BMSC toward
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Figure 2: MSC colony formation in media containing human serum. (a) Total number of colonies from 6 young (19-37 years old, left) and 4
old donors (65-79 years old, right), grown in StemMACS (SM) or media containing young donor serum (YS) or old donor serum (OS). (b)
Cell counts from cells grown in each of the serum conditions in the same 6 young (left) and 4 old (right) donor groups. Bars indicate median
values and whiskers represent interquartile ranges. (c) Frequency distribution of colony areas for all colonies from the same 6 young (left) and
4 old (right) donors grown in SM, YS, or OS conditions. (d) Comparison of IDs of all colonies from the same 6 young donors grown in SM
(345 colonies), YS (286 colonies), and OS (301 colonies) conditions. (e) Comparison of IDs of all colonies from the same 4 old donors grown
in SM (241 colonies), YS (175 colonies), and OS (170 colonies) conditions. Data in (d) and (e) is presented on log2 scale. Black lines represent
median values. ∗p < 0 05 and ∗∗∗∗p < 0 0001.
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adipocyte instead of osteoblastic fate,” reviewed in [31].
However, this has not been thoroughly investigated using
puriﬁed uncultured BM MSCs.
In this work, we used minimal MSC culture in the CFU-F
assay format to study proliferation of single adherent colony-
forming cells in relation to donor age. Sample collection and
processing were tightly controlled for BM aspiration and
processing, and a large cohort of individuals was recruited.
Consistent with published studies [5, 15, 20–22], we observed
a gradual decline in CFU-Fs with increasing donor age;
however, when the cohort was split into three age groups,
spanning two decades each, the bigger reduction in CFU-F
numbers was noted in the intermediate age group, compared
to the young age group, and not in the old group compared to
the intermediate age group. This was similar to the previously
reported data in Siegel et al.’s study [46] and could be related
to the highest bone turnover rates and hence a demand for
MSCs in individuals in their midtwenties (at their peak bone
mass), after which this demand declines gradually [47]. In
agreement with this idea, previous studies have documented
signiﬁcantly higher BM MSCs in children and adolescents
compared to adults and the elderly [20, 21, 48].
We next focussed on measuring colonies’ areas and inte-
grated densities in order to potentially identify a particular
105
104
103
102
101
105
104
103
102
101
105
104
103
102
101
101 102
CFU-F/ml
r = 0.606
p < 0.0001
1031000 20
r = –0.307
Males
CD
45
–
CD
27
1+
 ce
lls
/m
l
Females
p = 0.0116
40
Age (years)
60 80 100 19-40 41-60
Age (years)
61-89
(a)
⁎
101
100
10–1
10–2
10–3
10–4
10–1
10–2
10–3
102
101
100
10–1
10–2
10–3
102
101
100
10–1
10–2
10–3
101
100
CD271 HLC CD271 HLC
Young
Old
CD271 HLC
CD271 HLC CD271 HLC CD271 HLC
10–2
10–1
100
101
102
10–2
10–1
100
101
102
Re
lat
iv
e e
xp
re
ss
io
n
Re
lat
iv
e e
xp
re
ss
io
n
Be
lo
w
 d
et
ec
tio
n
Runx2
FABP4 PPAR-𝛾 LepR
SFRP1 SPARC
(b)
10–1
10–2
10–3
101
102
103
100
CD271 HLC
Young
Old
CD271 HLC
10–1
10–2
10–3
104
103
102
101
100
Re
lat
iv
e e
xp
re
ss
io
n
Re
lat
iv
e e
xp
re
ss
io
n
Cx43
CXCL12
(c)
Young
Old
CD271 HLC
CD271 HLC
10–1
10–2
10–3
10–4
101
100
10–1
10–2
10–3
10–4
10–5
101
100
Be
lo
w
 d
et
ec
tio
n
Re
lat
iv
e e
xp
re
ss
io
n
Re
lat
iv
e e
xp
re
ss
io
n
RANKL
OPG
⁎⁎
(d)
Figure 3: BM MSC enumeration and gene expression using CD45lowCD271+ phenotype. (a) Correlation between MSCs identiﬁed as
CD45lowCD271+ cells with donor age across complete age range (total 67 donors, left), between three age groups (centre), and
between CFU-F/ml and donor-matched CD45lowCD271+ cells/ml (right). Black lines across data sets indicate line of best ﬁt (left and
right) and median values for each group (centre). (b) Expression of transcripts associated with osteogenic (top) and adipogenic
diﬀerentiation (bottom). (c) Expression of transcripts associated with intercellular communication. (d) Expression of transcripts
associated with bone remodelling. Black and grey lines indicate median values with interquartile range in young and old donors,
respectively. ∗p < 0 05, ∗∗p < 0 01; n = 8 young donors (19-38 years old) and 8 old donors (61-89 years old). CD271: CD45lowCD271+
MSCs; HLC: CD45highCD271- hematopoietic lineage cells.
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colony type [42] that could be speciﬁcally aﬀected in older
age. Colony size distributions revealed no distinct segrega-
tion into “large” and “small” colonies; instead, the colony dis-
tributions in both younger and older donor groups were
unimodal. Nevertheless, compared to young donors, the inte-
grated densities of colonies from old donors were signiﬁ-
cantly lower, suggesting their reduced proliferative abilities.
From these results, it could be concluded that age-related
changes in human BM MSCs are associated with a general
reduction in proliferative capacities of all colony-forming
cells, rather a speciﬁc loss of the most proliferative progenitor
cell type.
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Figure 4: Surface marker expression in CD45lowCD271+ cells. (a) Gated populations and marker histograms from representative young
(19 years old) donor showing MSCs (top panel) and HLCs (bottom panel) with median ﬂuorescence intensity (MFI) indicated on the
right top corner. (b) Gated populations and marker histograms from representative old (67 years old) donor showing MSCs (top panel)
and HLCs (bottom panel) with MFI indicated on the right top corner. (c) Comparison of expression of selected surface markers in
8 young (19-38 years old, black) and 8 old (61-89 years old, grey) donor MSCs and HLCs with lines indicating median values with
interquartile ranges for each group. CD271: CD45lowCD271+ MSCs; HLC: CD45highCD271- hematopoietic lineage cells.
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We were mindful that these ﬁndings could simply reﬂect
humanMSC responses to speciﬁc CFU-F assay conditions, in
which culture media/serum are selected by the manufac-
turers or researchers to speciﬁcally enhance their in vitro
proliferation and expansion potentials. In order to validate
these ﬁndings using more “natural” culture conditions, we
performed similar experiments in media supplemented with
human serum. The eﬀects of human serum on MSCs have
been studied before [49, 50], but not at the single colony level.
In this study, we found that old donor serum had a negative
impact on colonies grown from both young and old donors
(they became smaller and less dense), possibly by increasing
oxidative stress levels in cells, as shown in a recent rat model
study [51], or via higher levels of proinﬂammatory cytokines
that are known to inhibit MSC proliferation [52]. Correlating
pro- and anti-inﬂammatory cytokine levels in serum from
young and old donors with their BM MSC number and col-
ony IDs or performing serum supplementation experiments
with the addition of antioxidants such as N-acetyl-cysteine
or superoxide dismutase may help to further address the
mechanisms of MSC proliferation inhibition. Conversely,
the integrated density of colonies from the young donor
group could be improved by cultivation in media containing
young donor serum as compared to old donor serum (by
21%, p < 0 0001) or SM (by 31%, p < 0 0001). A similar trend
was observed for the old donor group, but a signiﬁcant diﬀer-
ence (27%, p < 0 05) was only observed between YS and OS.
The limited responsiveness of old donor MSCs could be
due to reduced receptor levels for proliferation-promoting
growth factors, such as platelet-derived growth factors [53]
on their MSC surface. Altogether, these data indicated that
the type of serum is an important factor to consider in
MSC aging studies, even if MSCs are only cultured for a lim-
ited period of time. Nevertheless, colony numbers grown in
human serum were not markedly diﬀerent to those obtained
in the optimized expansion media conﬁrming the reliability
of MSC enumeration by colony scoring in FCS-containing
media. Our data also indicated that culturing old donor
MSCs in media containing young donor serum could mar-
ginally “rejuvenate” their proliferation ability. Diﬀerent strat-
egies including growing old donor MSCs on a young donor
extracellular matrix [54, 55] or with the addition of young
donor platelet lysate [56], as shown in previous studies,
may produce more substantial outcomes.
Since even minimal MSC expansion in diﬀerent human
sera has led to measurable diﬀerences in colony densities,
we next focussed on analysing in vivo MSC aging without
resorting to any expansion in vitro. For this, we chose to
quantify CD45lowCD271+ cells, a recognized phenotype of
BMMSCs, which has been validated in previous independent
studies [26, 28, 29, 36], as well as of MSCs resident in the adi-
pose tissue [28, 57]. We compared the ﬂow cytometry results
with our CFU-F ﬁndings, which were performed using the
same cohort of donors. While the results from the two assays
signiﬁcantly correlated with each other, the age-related
decline in CD45lowCD271+ cell population was notably less
pronounced than for CFU-Fs. This could be explained by
the fact that only a proportion of CD45lowCD271+ cells can
generate a colony in standard conditions (variable from 1
in 17 [27] to 1 in 40 [40]), which in this study was approxi-
mated to 1 in 26 or 1 in 48 in the young and old groups,
respectively. These results indicated an age-related decline
in MSC proliferation, conﬁrming our colony number and
integrated density data. A further study investigating the pro-
portions of senescent cells in rare sorted CD45lowCD271+
cells from young and old donors, using emerging methodol-
ogies [58], will help to clarify this point.
From MSC enumeration experiments, we next pro-
ceeded to measuring their osteo- and adipogenesis-related
gene expression using puriﬁed CD45lowCD271+ cells. The
data generated from long-term cultured MSCs (represent-
ing their “in vitro aging”) remain controversial. For exam-
ple, some studies including ours have previously shown
increased or unchanged levels of osteogenesis-related mole-
cules, in “in vitro aged” MSCs, paralleled with a decrease in
adipogenesis-related molecules [59, 60], in line with func-
tional measurements of their osteo- and adipogenic poten-
tials as functions of passages [7]. On the other hand, in vivo
observations of diminished trabecular bone volume [61]
and increased BM adiposity with increasing age [31] sug-
gested otherwise. In this study, we found nomajor diﬀerences
in adipogenesis-related transcript levels in CD45lowCD271+
cells from younger and older donors. The transcripts for
osteogenesis-related molecules from CD45lowCD271+ cells
also showed no age-related diﬀerences. In a separate study
using a smaller cohort of donors (n = 6, age range 24-62
years), we performed CFU-O (osteoblast) colony assays in
osteogenic media and no particular diﬀerences in the propor-
tions of alkaline phosphatase-positive colonies were observed
in relation to donor age. These preliminary experiments sup-
port our current ﬁndings on the similar basal levels of osteo-
genic gene expression in MSCs from old and young donors
and require further validation using larger donor cohorts.
Interestingly, the use of unfractionated bone marrow to study
the expression of mesenchymal lineage-deﬁning transcripts
revealed no signiﬁcant age relationships as well [62].
No diﬀerences in the expression were similarly found for
selected chemokine CXCL12 as well as Cx43/connexin 43
known to be involved in MSC communication with other
cells including hematopoietic stem cells [63]. This was unex-
pected as higher Cx43 transcript levels have been previously
found in paediatric CD45lowCD271+ cells compared to their
adult counterparts [34] and in young rat BM MSCs com-
pared to old rat MSCs [64]. Finally, interesting trends were
noted for the expression of genes involved in bone remodel-
ling, with both RANKL/receptor activator of nuclear factor
kappa-B ligand and its decoy receptor OPG/osteoprotegerin
showing higher expression levels in the older donor group.
Interestingly, recent experiments with mouse MSCs have
indicated a link between increased expression of RANKL
and age-related marrow adipogenesis [65].
Leptin receptor (LepR) is a well-known MSC-speciﬁc
molecule in mice [66, 67] and is involved in controlling mar-
row bone-fat balance in humans [68, 69]. We measured LepR
levels in CD45lowCD271+ cells, both at the gene expression
and protein levels and found its signiﬁcantly higher expres-
sion in MSCs compared to control HLCs, but no diﬀerences
in between younger and older donor groups. In contrast,
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LepR upregulation was described in in vitro aged MSCs and
linked with an increase is a subpopulation of dying cells
[33]. Finally, we used ﬂow cytometry to investigate the
expression of two other molecules (CD146 and CD106)
previously linked to in vitro MSC aging, on uncultured
CD45lowCD271+ BM cells. CD146 expression has been previ-
ously shown to decline in serially passaged MSCs [17, 46, 70].
Higher numbers of CD271+CD146+ cells were additionally
found in fetal and paediatric bone marrow compared to
adults [48]; however, our data revealed no signiﬁcant diﬀer-
ences in CD146 expression between the young and old donor
groups, most likely because the present cohort did not
include any paediatric donors. In relation to CD106, the liter-
ature pertaining to in vitro aged MSCs is controversial and
indicates either its decline [70, 71], increase [32], or random
oscillations [17] with passaging in standard culture condi-
tions. Similar to CD146, we found no diﬀerences in the levels
of CD106 expression on the surface of CD45lowCD271+ BM
cells in relation to donor age.
Altogether, our data reveal minimal transcriptional and
phenotypic changes in BM CD45lowCD271+ cells in old
donors compared to young donors. An age-related decline
in CD45lowCD271+ BM cells was observed but not to the
same degree as for CFU-Fs. Using the CFU-F assay and the
same cohort of donors, we found lower proliferative ability
of MSCs in older donors which was made worse with the
addition of serum from old donors. Finally, large donor
variation was observed in all age groups conﬁrming that a
person’s biological age in terms of their BM MSC status is
likely not to be the same as their chronological age.
Lower-than-expected diﬀerences in in vivo BMMSCs are
in contrast to what has been described for long-term cul-
tured, in vitro aged MSCs. This can be due to an enforced
proliferation and rapid replicative aging in cultured MSCs,
which do not normally occur in vivo where MSCs are nor-
mally quiescent. Even prior to their ﬁrst passage in culture,
MSCs normally undergo at least 10 population doublings
[5, 7, 20], and further passaging to 20 population doublings
has been estimated to “age” them by further 50 years, based
on the telomere loss measurements [5]. Given that MSCs
may in fact be long living and mostly quiescent in vivo [72],
age-related changes in these cells may be more subtle and
related to their metabolism or stress resistance, which would
be interesting to investigate in the future. Additionally,
recent studies have indicated that only a subpopulation of
CD45lowCD271+ BM cells may in fact be true self-renewing
MSCs [30, 73], and the investigations of gene expression in
these subpopulations are awaiting further investigation.
5. Conclusions
In summary, our data reveal a measurable reduction in
MSC colony number and integrated density, as well as
CD45lowCD271+ cell number in older donors, conﬁrming
an age-related decline in number and proliferative capacity
of MSCs. However, their selected multilineage gene expres-
sion proﬁles showed no age-related diﬀerences. In relation
to therapeutic applications with minimally manipulated
uncultured BM MSCs, our data indicate that old donor
MSCs may be inferior to young donor MSCs in regard to
their proliferation ability but not so much in terms of their
multipotential gene expression. Furthermore, a person’s
chronological age is not a reliable predictor of their MSC
number or potency, which merits further research to
develop new assays for MSC biological ﬁtness prior to their
use in therapy.
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